Discrepancies Discovered in the Treatment of People with Refractory Epilepsy by Epileptologists vs General Neurologists
Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory Epilepsy (US) study conducted by Spherix Global Insights (Exton, PA). Researchers found that general neurologists treat approximately 25% of people with epilepsy who have developed refractory epilepsy, constituting a significant proportion of the overall patient […]
Conflicting Views Between Epileptologists and General Neurologists Hinder Adoption of New Refractory Epilepsy Treatments
New brands aiming to enter the refractory epilepsy market may face challenges achieving desired penetration without improved general neurologist education efforts, according to Spherix Global Insights. EXTON, PA., July 8, 2024 – Chronic epilepsy is often well managed by neurologists, but a sizable proportion of adults with epilepsy continue to experience seizures at varying frequencies […]
US Neurologists Report Route of Administration as a Critical Factor when Evaluating Future Parkinson’s Disease Treatments
US Neurologists express enthusiasm for new ways to administer current treatments and future disease modifying therapies, according to Spherix Global Insights. EXTON, PA., May 9, 2024 – Even as the incidence of Parkinson’s disease (PD) continues to increase with 90,000 new diagnoses each year1 in the US, the treatment landscape has remained relatively stagnant. Yet, neurologists […]
Leqembi launch hamstrung by physicians’ ‘therapeutic nihilism’
Eisai has recently outlined a range of ways to kick-start Leqembi’s lackluster launch, from increasing the number of neurology account specialists to adding a subcutaneous option. But a Reuters report suggests the company faces a more fundamental problem: Physicians still see Alzheimer’s disease as untreatable. The Japanese drugmaker said 2,000 patients in the U.S. were receiving the amyloid-busting antibody […]
How Do Companies Avert Further Frustration Among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
Spherix Global Insights captures neurologists’ reactions within 48 hours of these pivotal announcements. EXTON, PA., March 12, 2024 — For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming months may prove equally heart-wrenching. They face the daunting responsibility of informing patients and caregivers that not […]
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, According to Spherix Global Insights Neurologist Survey
Adoption of Leqembi is even slower than expected. EXTON, PA., February 22, 2024 — The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical community and among families nationwide. The debut of Aduhelm from Biogen in 2021 brought with it a wave of […]
Parkinson’s Disease Patient Identification and Education Will Need to Improve When New Disease Modifying Therapies Are Approved, According to Spherix Global Insights
Earlier screening will be needed in the age of biomarkers. EXTON, PA., February 16, 2024 — Millions of people worldwide are affected by Parkinson’s disease (PD), prompting the need for effective disease-modifying therapies (DMTs) to target this degenerative condition. With gene therapies emerging as an exciting potential mechanism of action (MOA) for future treatment, their […]
Potential for new Huntington’s treatment sparks optimism for MDs
But US neurologists also express frustration with current lack of therapies Neurologists in the U.S. are optimistic about the potential for a new treatment for Huntington’s disease, but emphasize the need for therapies that halt nerve degeneration before symptom onset, according to a report by Spherix Global Insights. Most of the specialist physicians surveyed hoped for a […]
US Neurologists Optimistic Regarding the Huntington’s Disease Treatment Pipeline, Emphasizing Halting Neurodegeneration as Leading Treatment Priority
According to Spherix Global Insights’ first market landscape study on Huntington’s disease, neurologists are staking their hopes on gene therapy. EXTON, Pa., January 3, 2024 – Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not only motor function – causing symptoms […]
US neurologists favorably view BTK inhibitors as potential MS therapies
But Spherix surveys across 2023 may not reflect recent setbacks in clinical trials More than one-third of neurologists in the U.S. believe Bruton’s tyrosine kinase (BTK) inhibitors could be of pivotal significance as a future treatment of multiple sclerosis (MS), according to findings of a recent Spherix Global Insights’ survey. “Through Spherix’s quarterly RealTime Dynamix market tracker, neurologists and […]
